Human tumor procoagulants: registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society on Thrombosis and Haemostasis
Edwards, R.L.; Silver, J.; Rickles, F.R.
Thrombosis and Haemostasis 69(2): 205-213
1993
ISSN/ISBN: 0340-6245 PMID: 8456435 Document Number: 412209
In 1986, the Subcommittee on Haemostasis and Malignancy of the International Committee on Thrombosis and Haemostasis agreed that a need existed for an international registry of the properties of tumor procoagulants. Two registries were planned: (1) one of procoagulants in experimental animal tumor models; (2) a registry of human tumor procoagulants. The registries were planned to be organized so as to fulfill several functions. They would serve as single, regularly updated source for investigators who desired information on various tumor models. In addition, it was hoped that a concise summary of the biologic and biochemical properties of tumor procoagulants could be accomplished in a format designed for easy access and frequent revision. In addition, the registries were meant to include sufficient general information regarding the techniques used to characterize the procoagulants in the cited studies to stimulate discussion of key methodologic differences and controversies. A working group was formed and a review of tumour procoagulants in experimental animal models was published in this journal in 1990 (1). The present communication represents the second phase of the activity of this working group: a registry of the properties of human tumour procoagulants. The Subcommittee hopes that these registries will stimulate and support additional investigation of the properties and clinical significance of tumor procoagulants. Moreover, the authors hope that investigators will be provided new information for subsequent updates of both registries by the readership of the journal. For that purpose, the FAX of the corresponding author is included. A more detailed overview of this subject and the potential pathophysiologic role of tumor procoagulants appears elsewhere (2).